BRAF mutations have been implicated in the pathogenesis of different cancers, including melanoma, colorectal cancer, non-small cell lung cancer, papillary thyroid cancer, and ovarian cancer (1, 2). The V600E mutation, the most common mutation of BRAF gene, has been shown to negatively affect the anti-EGFR therapies for metastatic colorectal cancers but increase the sensitivity to BRAF kinase inhibitors for the melanoma treatment (3, 4).
TrimGen's BRAF mutation analysis is designed for two platforms:
- Multiple mutations > choose Fragment Analysis based BRAF Mutation Detection Kit
- Only V600E > choose Real-time PCR based BRAF Mutation Detection Kit
Order Information
| Cat. No. | Product Name | Mutations Interrogated | Size | Documents |
| GP02-EK | Mutector BRAF Mutation Analysis | 5 BRAF Mutations in Codon 600 | 32 rxn | Manual |
| EP12 | eQ-PCR BRAF Mutation Analysis | BRAF V600E | 32 rxn | Manual |
For research use only. Not for use in diagnostic procedures.
Related Products
- FFPE Sample DNA Extraction– high yield DNA in 1 hour, 99% PCR success rate
- Mutation Analysis Reagents for Oncology – single platform for any somatic mutation
- Mutation Analysis Reagents for Pharmacogenetics – single platform for any genotyping
References
- Davies H et al. (2002). Mutations of the BRAF gene in human cancer. Nature 417:949.
- Di Nicolantonio F et al. (2008). Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 26:5705.
- De Roock W et al. (2011). KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer. Lancet Oncol 12:594.
- Chapman PB et al. (2011). Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364:2507.